Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 98 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2017

Summary

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 39 molecules. Out of which approximately 36 molecules are developed by companies and remaining by the universities/institutes. The latest report Nuclear Receptor ROR Gamma - Pipeline Review, H2 2017, outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - RAR-related orphan receptor gamma (ROR?) is a protein encoded by the RORC gene. ROR? is member of the nuclear receptor family of transcription factors. It exist in two isoforms ROR? and ROR?t. ROR? is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R OR?t, appears to be highly restricted to the thymus. ROR? isoform is involved in the regulation of circadian rhythms and ROR?t plays an important regulatory role in thymopoiesis and in inhibiting apoptosis.  The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 20, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Dermatology, Metabolic Disorders and Other Diseases which include indications Psoriasis, Rheumatoid Arthritis, Autoimmune Disorders, Inflammation, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriatic Arthritis, Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis (NASH), Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Asthma, Axial Spondyloarthritis, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Metastatic Cancer, Neuromyelitis Optica (Devic's Syndrome), Orphan Diseases, Skin Inflammation, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes). 

Furthermore, this report also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
- The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development
AbbVie Inc
Advinus Therapeutics Ltd
Allergan Plc
Arrien Pharmaceuticals LLC
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biogen Inc
Brickell Biotech Inc
Bristol-Myers Squibb Company
Celgene Corp
Eli Lilly and Company
Genentech Inc
Genfit SA
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Lead Pharma Holding BV
Lycera Corp
Maruho Co Ltd
Nuevolution AB
Orphagen Pharmaceuticals Inc
Pfizer Inc
Phenex Pharmaceuticals AG
Reata Pharmaceuticals Inc
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles
ABBV-553 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARN-6039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0284 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBI-6000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRC-39815 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2981278 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMU-366 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-71 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-3534 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTE-451 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LYC-55716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LYC-56056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROR Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis and Psoriatic Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROR Gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit RORC for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-2211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TGFTX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMP-778 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPR-66 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTP-43742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTP-45489 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones
Featured News & Press Releases
Jul 10, 2017: Phenex announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I
Jan 04, 2017: Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors
Nov 04, 2016: Lycera Announces Publication of Immuno-Oncology Research, Demonstrating Differentiated Mechanism of RORgamma Agonists
Sep 26, 2016: GENFIT: Successful identification of RORt inverse agonists as candidates for regulatory pre-IND studies
Aug 01, 2016: Arrien Pharmaceuticals Provides Update on ARN-6039
Jun 06, 2016: Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer
Jun 03, 2016: Arrien Pharmaceuticals Initiated Phase I Clinical Trials of ARN-6039 as a New Agent for Treatment of Multiple Sclerosis
May 16, 2016: Arrien Pharmaceuticals Initiates Phase I Clinical trials of ARN-6039
May 09, 2016: Arrien Pharmaceuticals to Initiate the Phase I Clinical trials of Autoimmune Drug
Apr 29, 2016: Arrien Pharmaceuticals Announces FDA Accepts IND Application For ARN-6039
Apr 19, 2016: Lycera Announces Progress in Immuno-Oncology Program Presented at the 2016 American Association for Cancer Research Annual Meeting
Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis
Dec 17, 2015: Phenex reaches milestone in collaboration with Janssen
Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742
Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1)
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by AbbVie Inc, H2 2017
Pipeline by Advinus Therapeutics Ltd, H2 2017
Pipeline by Allergan Plc, H2 2017
Pipeline by Arrien Pharmaceuticals LLC, H2 2017
Pipeline by AstraZeneca Plc, H2 2017
Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017
Pipeline by Biogen Inc, H2 2017
Pipeline by Brickell Biotech Inc, H2 2017
Pipeline by Bristol-Myers Squibb Company, H2 2017
Pipeline by Celgene Corp, H2 2017
Pipeline by Eli Lilly and Company, H2 2017
Pipeline by Genentech Inc, H2 2017
Pipeline by Genfit SA, H2 2017
Pipeline by GlaxoSmithKline Plc, H2 2017
Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
Pipeline by Lead Pharma Holding BV, H2 2017
Pipeline by Lycera Corp, H2 2017
Pipeline by Maruho Co Ltd, H2 2017
Pipeline by Nuevolution AB, H2 2017
Pipeline by Orphagen Pharmaceuticals Inc, H2 2017
Pipeline by Pfizer Inc, H2 2017
Pipeline by Phenex Pharmaceuticals AG, H2 2017
Pipeline by Reata Pharmaceuticals Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017